Skip to main content
logo
Structure Therapeutics Inc. (GPCR)
NASDAQ: GPCR · Real-Time Price · USD
49.09
-1.43 (-2.83%)
At close: Aug 21, 2026, 4:00 PM EDT
49.20
+0.11 (0.22%)
After-hours: Aug 21, 2026, 7:59 PM EDT

Structure Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
73.8161.5549.4132.6716.378.59
Research & Development
294.24225.26108.8170.136.1929.11
Other Operating Expenses
-100-100----
Operating Expenses
268.06186.81158.23102.7852.5637.7
Operating Income
-268.06-186.81-158.23-102.78-52.56-37.7
Interest Expense
------0.12
Interest & Investment Income
46.5735.8736.0113.391.26-
EBT Excluding Unusual Items
-221.48-150.94-122.22-89.38-51.3-37.82
Gain (Loss) on Sale of Assets
10.2510.25----
Pretax Income
-214.13-140.69-122.22-89.38-51.3-37.82
Income Tax Expense
0.70.520.310.240.020.23
Net Income
-214.84-141.2-122.53-89.62-51.32-38.05
Preferred Dividends & Other Adjustments
----1.525.72
Net Income to Common
-214.84-141.2-122.53-89.62-52.84-43.77
Net Income Growth
------
Shares Outstanding (Basic)
6759533733
Shares Outstanding (Diluted)
6759533733
Shares Change
16.35%12.46%43.31%1049.81%17.72%30.01%
EPS (Basic)
-3.22-2.39-2.33-2.44-16.54-16.13
EPS (Diluted)
-3.22-2.39-2.33-2.44-16.54-16.13
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-224.5-225.81-117.93-81.66-46.28-33.37
Free Cash Flow Per Share
-3.36-3.81-2.24-2.22-14.48-12.30
EBITDA
-265.79-185.13-157.23-102.46-52.28-37.62
D&A For EBITDA
2.271.6810.320.280.07
EBIT
-268.06-186.81-158.23-102.78-52.56-37.7
SEC Filings: 10-K · 10-Q